New Delhi, Apr 6 (UNI) After its foray into Nepal, a cancer diagnostic firm Dabur OncQuest plans for massive global expansion by spreading its network in Sri Lanka, Philippines, Malaysia, and the Gulf region in the next three years, beside getting into the US and European market.
''We are in talks with the local firms in Colombo, Manila, Kaula Lumpur and Dubai, and hope to start commercial operations in the next two-three years,'' Dabur Pharma Ltd Head (Diagnostic) Vivek Trikha told UNI.
The subsidiary of Dabur Pharma Ltd also sees opportunity in the US and the European market.
''Our paper work is complete for starting the operations in the US but waiting for the approval from the regulatory body. We can launch the operations the very next day of getting regulatory nod,'' Mr Trikha added.
On April 3, the company has announced its foray into Nepal through a tie-up with a local firm Annapurna Diagnostic to provide testing facilities for cancer patients.
''Kathmandu being the business hub of Nepal was zeroed down as the best location for collection centre. Through this, the patients in Nepal will now have access to all the technically advanced and cost-effective diagnostic tests being offered by Dabur OncQuest in India,'' Mr Trikha said.
The company did a pilot run and diagnosed samples of over 200 patients leading to business of more than 15 lakhs, he added.
''With the successful and much appreciated completion of the project, we have won the confidence of doctors and patients. We are pleased to announce our full-fledged services in Nepal through our first commercial collection center in Kathmandu,'' Mr Trikha said.
The company plans to further develop two more collection centres at Bharatpur and Chitwann in Nepal.
Dabur OncQuest, started its operations in 2003, has expertise to evaluate the structure of DNA, RNA and proteins in cells.
UNI MP RKM PM1445